Key facts
- This page summarizes Robin Shane Readnour's Form 3 filing for AN2 Therapeutics, Inc. (ANTX).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 24 Mar 2022, 21:21.
Robin Shane Readnour - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Director
- Issuer ticker
- ANTX
- Reported as of
- 24 Mar 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 24 Mar 2022, 21:21:08 UTC
- Next SEC filing
- 31 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Robin Shane Readnour
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robin Shane Readnour filed Form 3 for AN2 Therapeutics, Inc. (ANTX) on 24 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANTX
holding
Derivative
Series A Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2022
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 285,156
- Exercise price
- Footnotes
- F1, F2, F4
ANTX
holding
Derivative
Series A Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2022
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 333,135
- Exercise price
- Footnotes
- F1, F3, F4
ANTX
holding
Derivative
Series B Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2022
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 61,491
- Exercise price
- Footnotes
- F1, F2, F4
ANTX
holding
Derivative
Series B Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Mar 2022
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 71,839
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
Footnote F2
Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP").
Footnote F3
Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP").
Footnote F4
MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
SEC remarks
Exhibit 24 - Power of Attorney